Throughput: 480 tests/hour 580 tests/hour with ISE
Test items on board: 36 items + ISE 3 items
Reaction volume: 120– 300 micro-liter
Patient samples on board: 72 patient samples, 30 STAT samples
Reaction volume: 140– 300 micro-liter
Test items on board: 24 items + ISE 3 items / 36 items + ISE 3 items
Patient samples on board: 30 patient samples
Throughput: 270 tests/hour 450 tests/hour with ISE
R1: 140 ～ 300μl (1μl step）
R2: 20 ～ 260μl (1μl step）
News and Announcements
The number of deaths from cervical cancer in the USA has decreased substantially since the implementation of widespread cervical cancer screening and has declined from 2.8 to 2.3 deaths per 100,000 women from 2000 to 2015. The evidence on screening for cervical cancer has been reviewed with a focus on clinical trials and cohort studies that evaluated screening with high-risk human papillomavirus (hrHPV) testing alone or hrHPV and cytology together (co-testing) compared with cervical cytology alone.
The US Preventive Services Task Force (Rockville, MD, USA) besides reviewing and evaluating cervical cancer screening also commissioned a decision analysis model to evaluate the age at which to begin and end screening, the optimal interval for screening, the effectiveness of different screening strategies, and related benefits and harms of different screening strategies. The experts reported on screening with cervical cytology alone, primary hrHPV testing alone, or co-testing can detect high-grade precancerous cervical lesions and cervical cancer. Screening women aged 21 to 65 years substantially reduces cervical cancer incidence and mortality. The harms of screening for cervical cancer in women aged 30 to 65 years are moderate. Four studies identified in the review found that primary hrHPV testing detected higher rates of stage 3 (or worse) cervical intraepithelial neoplasia compared with the standalone Pap test in the first round of testing. In comparing the Pap, hrHPV and co-testing methods, the latter two methods were associated with higher colposcopy and false-positive rates.
The scientists concluded with high certainty that the benefits of screening every three years with cytology alone in women aged 21 to 29 years substantially outweigh the harms. They also concluded with high certainty that the benefits of screening every three years with cytology alone, every five years with hrHPV testing alone, or every five years with both tests (co-testing) in women aged 30 to 65 years outweigh the harms. Screening women older than 65 years who have had adequate prior screening and women younger than 21 years does not provide significant benefit. The anticipation is hrHPV testing every five years for women aged 30 to 65 could reduce cervical cancer mortality from 8.34 to 0.29 deaths per 1,000 women.LabMedica
Mycobacterium leprae is the causative agent of leprosy, a chronic granulomatous infectious disease affecting the skin and peripheral nerves. Leprosy manifests in various forms based on the immunological profiles and bacterial load in patients.
The diagnosis of leprosy mainly relies on clinical examination due to the inconsistent sensitivity and poor reproducibility of the current laboratory tests. Utilization of alternative methods to the standard Ziehl Neelsen (ZN), Fite-Faraco (FF) and Haematoxylin and Eosin (H&E) staining procedures may eventually improve leprosy diagnosis.
Ethiopian and Swiss scientists working at the Armauer Hansen Research Institute (Addis Ababa, Ethiopia) enrolled a total of 141 leprosy cases comprising 136 newly diagnosed treatment naïve and five relapse leprosy patients with any form of the disease in a prospective comparative cross-sectional study at the ALERT center from January 2015 to April 2016.
The team compared the performance of the fluorescent Auramine O (AO) staining and polymerase chain reaction (PCR) with different skin samples using a combination of ZN, FF and H&E staining as the gold standard. AO, ZN, FF, H&E and PCR tests were performed on slit skin smears (SSS). DNA was extracted from punch biopsies using two different methods with or without mechanical lysis. Punch biopsies in 10% formalin were kept for 48–72 hours before tissue processing was performed overnight using an automated tissue processor ASP 300S.LabMedica
Cardiovascular disease generally refers to conditions that involve narrowed or blocked blood vessels that can lead to a heart attack, chest pain (angina) or stroke. Cardiovascular disease (CVD) risk prediction represents an increasing clinical challenge in the treatment of diabetes.
A panel of vascular imaging, functional assessments, and biomarkers reflecting different disease mechanisms has been used to identify clinically useful markers of risk for cardiovascular (CV) events in subjects with type 2 diabetes (T2D) with or without manifest CVD. A team of scientists led by those at the University of Exeter (Exeter, UK) recruited 936 subjects with T2D at four European centers. Carotid intima-media thickness and plaque area, ankle-brachial pressure index, arterial stiffness, endothelial function, and circulating biomarkers were analyzed at baseline, and CV events were monitored during a three-year follow-up period.
The investigators reported that the CV event rate in 440 subjects with T2D was statistically higher in those with than in those 496 without manifest CVD at baseline (5.53 versus 2.15/100 life-years). New CV events in subjects with T2D with manifest CVD were associated with higher baseline levels of inflammatory biomarkers such as interleukin 6, chemokine ligand 3, pentraxin 3, and high sensitivity C-reactive protein (hs-CRP) and endothelial mitogens represented by, hepatocyte growth factor and vascular endothelial growth factor A. However, CV events in subjects with T2D without manifest CVD were associated with more severe baseline atherosclerosis (median carotid plaque area 34.5 mm2 versus 19.5 mm2. Conventional risk factors, as well as measurements of arterial stiffness and endothelial reactivity, were not associated with CV events.
The authors concluded that their observations demonstrate that markers of inflammation and endothelial stress reflect CV risk in subjects with T2D with manifest CVD, whereas the risk for CV events in subjects with T2D without manifest CVD is primarily related to the severity of atherosclerosis. The study was published on July 6, 2018, in the journal Diabetes Care.LabMedica
Obstructive sleep apnea is a disorder in which breathing is repetitively interrupted during sleep due to collapse of the upper airway. An apnea is defined as complete cessation of breathing lasting 10 seconds or greater.
Dyslipidemia is an abnormal amount of lipids such as triglycerides, cholesterol and/or fat phospholipids in the blood. Both obstructive sleep apnea (OSA) and dyslipidemia are independent risk factors for cardiovascular disease.
An international team of investigators led by scientists at the Sahlgrenska Academy (Gothenburg, Sweden) carried out a cross‐sectional analysis that included 8,592 patients without physician‐diagnosed hyperlipidemia or reported intake of a lipid‐lowering drug (age 50.1 ± 12.7 years, 69.1% male, BMI: 30.8 ± 6.6 kg/m2, mean apnea–hypopnea index (AHI): 25.7 ± 25.9 events/hour). The independent relationship between measures of OSA (AHI, oxygen desaturation index (ODI), mean and lowest oxygen saturation) and lipid profile (total cholesterol (TC), high‐density was calculated.LabMedica
Subscribe to our newsletter to receive news, updates, and another stuff by email.